1. TOP
  2. NEWS
  3. 【News_EN】 collab-EN
  4. Concluded a joint research agreement with Sumitomo Dainippon Pharma


Concluded a joint research agreement with Sumitomo Dainippon Pharma

  • このエントリーをはてなブックマークに追加
Concluded  a joint research agreement with Sumitomo Dainippon Pharma

TOKYO,Japan – 24 March, 2022.  RevolKa Ltd., a biotech company focused on the discovery of protein therapeutics using its proprietary artificial intelligence platform, today announced a research collaboration agreement with Sumitomo Dainippon Pharma Co., Ltd. (“Sumitomo Dainippon Pharma”).  Under the research collaboration, RevolKa will use its proprietary evolutionary molecular engineering platform technology, aiProteinTM Technology, to discover new protein drug candidates for the treatment of rare diseases.  Sumitomo Dainippon Pharma will receive first refusal rights towards an exclusive license necessary for the business to the achievements generated by the research collaboration, in which license proteins applied with the aiProteinTM Technology are defined in the agreement. “We are excited to have Sumitomo Dainippon Pharma as a partner, and the opportunity to demonstrate the power of the platform, aiProteinTM, that combines AI and evolutionary molecular engineering," said Shiro Kataoka, Ph.D., Chief Executive Officer of RevolKa Ltd.  "We look forward to contributing to the health of people around the world through this collaboration," Dr. Kataoka continued. Of note, the collaboration includes proteins pre-defined in the agreement.  Financial terms were not disclosed.

About aiProteinTM Technology
RevolKa’s proprietary aiProteinTM Technology was developed under a research collaboration between Tohoku University, National Institute of Advanced industrial Science and Technology (AIST) and the University of Tokyo.  aiProteinTM Technology combines artificial intelligence and machine learning with evolutionary molecular engineering to create novel proteins.  The technology enables the creation of highly-optimized proteins both cost effectively and within very rapid timelines.  In addition to the development of biopharmaceuticals, aiProteinTM Technology will have uses in food and industrial applications, and other areas.

About RevolKa Ltd.
RevolKa is a venture-backed biotechnology company founded in April 2021 by academic and industry experts in the use of artificial intelligence and protein engineering.  The name "RevolKa" is derived from the Latin word for evolution (evolutio) and the Ainu word for raise (reska), and captures RevolKa’s mission in creating novel, functional proteins through the use of evolutionary molecular engineering that mimics evolution in silico by using artificial intelligence as a guide.   RevolKa’s headquarters are based in Tokyo, Japan with laboratories located in Sendai and Tokyo.  The company’s investors include Tohoku University Venture Partners.

About Sumitomo Dainippon Pharma Co., Ltd.
Sumitomo Dainippon Pharma Co., Ltd. defines its corporate mission as to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide. By channeling our efforts into the research and development of new drugs, Sumitomo Dainippon Pharma aims to realize our mission and provide innovative and effective pharmaceutical solutions not only to people in Japan but also around the world.
For more information, please visit https://www.ds-pharma.com/. 

220324_Press release(RevolKaーDSP).pdf

  • このエントリーをはてなブックマークに追加